Fisher Matthew B, Belkin Nicole S, Milby Andrew H, Henning Elizabeth A, Söegaard Nicole, Kim Minwook, Pfeifer Christian, Saxena Vishal, Dodge George R, Burdick Jason A, Schaer Thomas P, Steinberg David R, Mauck Robert L
McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Translational Musculoskeletal Research Center, Philadelphia VA Medical Center, Philadelphia, PA, USA; Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC, USA; North Carolina State University, Raleigh, NC, USA.
McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Translational Musculoskeletal Research Center, Philadelphia VA Medical Center, Philadelphia, PA, USA.
Cartilage. 2016 Apr;7(2):174-84. doi: 10.1177/1947603515623030. Epub 2015 Dec 28.
We have recently shown that mesenchymal stem cells (MSCs) embedded in a hyaluronic acid (HA) hydrogel and exposed to chondrogenic factors (transforming growth factor-β3 [TGF-β3]) produce a cartilage-like tissue in vitro. The current objective was to determine if these same factors could be combined immediately prior to implantation to induce a superior healing response in vivo relative to the hydrogel alone.
Trochlear chondral defects were created in Yucatan mini-pigs (6 months old). Treatment groups included an HA hydrogel alone and hydrogels containing allogeneic MSCs, TGF-β3, or both. Six weeks after surgery, micro-computed tomography was used to quantitatively assess defect fill and subchondral bone remodeling. The quality of cartilage repair was assessed using the ICRS-II histological scoring system and immunohistochemistry for type II collagen.
Treatment with TGF-β3 led to a marked increase in positive staining for collagen type II within defects (P < 0.05), while delivery of MSCs did not (P > 0.05). Neither condition had an impact on other histological semiquantitative scores (P > 0.05), and inclusion of MSCs led to significantly less defect fill (P < 0.05). For all measurements, no synergistic interaction was found between TGF-β3 and MSC treatment when they were delivered together (P > 0.05).
At this early healing time point, treatment with TGF-β3 promoted the formation of collagen type II within the defect, while allogeneic MSCs had little benefit. Combination of TGF-β3 and MSCs at the time of surgery did not produce a synergistic effect. An in vitro precultured construct made of these components may be required to enhance in vivo repair in this model system.
我们最近发现,嵌入透明质酸(HA)水凝胶并暴露于软骨形成因子(转化生长因子-β3 [TGF-β3])的间充质干细胞(MSC)在体外可产生类似软骨的组织。当前的目的是确定这些相同的因子在植入前立即联合使用是否能相对于单独的水凝胶在体内诱导出更好的愈合反应。
在尤卡坦小型猪(6个月大)中制造滑车软骨缺损。治疗组包括单独的HA水凝胶以及含有同种异体MSC、TGF-β3或两者的水凝胶。手术后6周,使用微型计算机断层扫描定量评估缺损填充和软骨下骨重塑情况。使用国际软骨修复协会(ICRS-II)组织学评分系统和II型胶原免疫组织化学评估软骨修复质量。
用TGF-β3治疗导致缺损内II型胶原阳性染色显著增加(P < 0.05),而MSC的递送则没有(P > 0.05)。两种情况对其他组织学半定量评分均无影响(P > 0.05),并且包含MSC导致缺损填充明显减少(P < 0.05)。对于所有测量,当TGF-β3和MSC联合递送时未发现协同相互作用(P > 0.05)。
在这个早期愈合时间点,用TGF-β3治疗促进了缺损内II型胶原的形成,而同种异体MSC几乎没有益处。手术时TGF-β3和MSC联合使用未产生协同效应。在该模型系统中可能需要由这些成分制成的体外预培养构建体来增强体内修复。